ライフサイエンスコーパス: sclerosing cholangitis

1 for potentially recurrent diseases (primary sclerosing cholangitis).

2 response such as alcoholic liver disease or sclerosing cholangitis.

3 kocytes, and abrogates progression of murine sclerosing cholangitis.

4 t both primary biliary cirrhosis and primary sclerosing cholangitis.

5 ity of primary biliary cirrhosis and primary sclerosing cholangitis.

6 static entities, primary (PSC) and secondary sclerosing cholangitis.

7 ones, primary biliary cirrhosis, and primary sclerosing cholangitis.

8 n may be considered as potential therapy for sclerosing cholangitis.

9 ngitis and the steroid-nonresponsive primary sclerosing cholangitis.

10 from UC that is not associated with primary sclerosing cholangitis.

11 f 38.5% observed among patients with primary sclerosing cholangitis.

12 n haplotypes are not associated with primary sclerosing cholangitis.

13 itis, primary biliary cirrhosis, and primary sclerosing cholangitis.

14 nancy, primary biliary cirrhosis and primary sclerosing cholangitis.

15 on does not appear to directly cause primary sclerosing cholangitis.

16 ve been detected in liver tissues in primary sclerosing cholangitis.

17 c disease, chronic pancreatitis, and primary sclerosing cholangitis.

18 ancy, primary biliary cirrhosis, and primary sclerosing cholangitis.

19 established long-term treatment for primary sclerosing cholangitis.

20 otein 2 knockout (Mdr2(-/-) ) mouse model of sclerosing cholangitis.

21 on in a patient with sickle cell disease and sclerosing cholangitis.

22 nset or immediately in patients with primary sclerosing cholangitis.

23 n age was 49, and 88% had underlying primary sclerosing cholangitis.

24 epresented 5.8% of patients (18 of 309) with sclerosing cholangitis.

25 patients with ulcerative colitis and primary sclerosing cholangitis.

26 e, respectively) and subjected to a model of sclerosing cholangitis.

27 There were 7 patients with primary sclerosing cholangitis.

28 ng human cholangiopathies, including primary sclerosing cholangitis.

29 effects to severe disorders, such as primary sclerosing cholangitis.

30 ous complications in patients with secondary sclerosing cholangitis.

31 f ERC, especially in patients with secondary sclerosing cholangitis.

32 iary tuberculosis with features of secondary sclerosing cholangitis.

33 tal antimicrobials were those with secondary sclerosing cholangitis.

34 Still rarer is its presentation as sclerosing cholangitis.

35 ociation studies as risk factors for primary sclerosing cholangitis.

36 amilial intrahepatic cholestasis and primary sclerosing cholangitis.

37 MC mediators may be therapeutic for primary sclerosing cholangitis.

38 primary biliary cirrhosis (16%), and primary sclerosing cholangitis (13%) with an odds ratio of 2.3,

39 ls with autoimmune diseases (18 with primary sclerosing cholangitis, 16 with autoimmune hepatitis, an

40 vs. 0.6%), hepatobiliary (including primary sclerosing cholangitis) (5.5% vs. 0.1%), pancreatic (1.7

41 ancies (46.4%) and 114 patients with primary sclerosing cholangitis (62.3%).

42 Primarily indications for ERC were sclerosing cholangitis (75%) and malignant stenosis (9.5

43 iver and bile duct injury in mouse models of sclerosing cholangitis, a disease so far lacking effecti

44 itis, extensive colonic involvement, primary sclerosing cholangitis, a family history of colorectal c

45 une pancreatitis in association with primary sclerosing cholangitis, a syndrome with distinct clinico

46 primary biliary cirrhosis [PBC], and primary sclerosing cholangitis) account for approximately one th

47 1.34-2.74), and lower likelihood of primary sclerosing cholangitis (adjusted odds ratio 0.38; 95% CI

48 in autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (AISC) either through inability o

49 in CLDs (primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease, and chr

50 ues were obtained from patients with primary sclerosing cholangitis, alcoholic liver disease, or nona

51 Primary biliary cirrhosis, primary sclerosing cholangitis and biliary atresia are thought t

52 nd pancreas is difficult to distinguish from sclerosing cholangitis and biliary/pancreatic malignanci

53 re up-regulated by cholangiocytes in primary sclerosing cholangitis and cholangiocarcinoma.

54 also detected in human patients with primary sclerosing cholangitis and hepatobiliary cholangiopathie

55 Primary sclerosing cholangitis and immunosuppressive use were no

56 astic bile duct inflammatory disease primary sclerosing cholangitis and in human cholangiocarcinoma s

57 1.9, P < .005) and in patients with primary sclerosing cholangitis and in severity were independentl

58 ular, the strong comorbidity between primary sclerosing cholangitis and inflammatory bowel disease is

59 apies for primary biliary cirrhosis, primary sclerosing cholangitis and intrahepatic cholestasis.

60 AP in the bile ductular reactions of primary sclerosing cholangitis and primary biliary cirrhosis pat

61 immune-mediated diseases, including primary sclerosing cholangitis and primary biliary cirrhosis, bu

62 dylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis to investi

63 lymphedema, protein loosing enteropathy, and sclerosing cholangitis and was diagnosed with lymphedema

64 en, with only 7 patients having a history of sclerosing cholangitis and/or inflammatory bowel disease

65 s (or any duration, if they also had primary sclerosing cholangitis) and no history of advanced CRN (

66 ic cholestasis, biliary atresia, and primary sclerosing cholangitis, and clinical trials of therapies

67 Patients with autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis as

68 rent autoimmune hepatitis, recurrent primary sclerosing cholangitis, and recurrent primary biliary ci

69 ncluding autoimmune hepatitis and autoimmune sclerosing cholangitis ASC).

70 ary sclerosing cholangitis (PSC), autoimmune sclerosing cholangitis (ASC), and autoimmune hepatitis (

71 gnoses of primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, hepatitis

72 including primary biliary cirrhosis, primary sclerosing cholangitis, biliary atresia, and progressive

73 CC, including parasitic infections, primary sclerosing cholangitis, biliary-duct cysts, hepatolithia

74 sitive biliary strictures resembling primary sclerosing cholangitis but with increased serum immunogl

75 rable with those in patients without primary sclerosing cholangitis, but there is a higher rate of re

76 s liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.

77 Differentiation of primary sclerosing cholangitis can be challenging because other

78 may play a role in biliary atresia, primary sclerosing cholangitis, cellular rejection, and primary

79 atment of primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy, and dr

80 atment of primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy, total

81 including primary biliary cirrhosis, primary sclerosing cholangitis, chronic hepatitis C, and postnec

82 samples (15 CCAs and 20 nonmalignant primary sclerosing cholangitis controls), and the methylation st

83 arkers was validated (34 CCAs and 34 primary sclerosing cholangitis controls).

84 In a subgroup of patients, sclerosing cholangitis develops, which may lead to end-s

85 gram results, but the syndrome of autoimmune sclerosing cholangitis does not affect immediate prognos

86 in in Mdr2 knockout (KO) mice, which develop sclerosing cholangitis due to regurgitation of BA from l

87 r data collected included history of primary sclerosing cholangitis, family history of colorectal can

88 rbonyl-1,4-dihydrocollidine (DDC; a model of sclerosing cholangitis) for 4 weeks.

89 ural history of large and small duct primary sclerosing cholangitis has been reviewed.

90 Patients with primary sclerosing cholangitis have a poor prognosis; progressio

91 f patients previously diagnosed with primary sclerosing cholangitis have autoimmune pancreatitis in a

92 s associated with protection against primary sclerosing cholangitis have been elucidated.

93 antigen haplotype associations with primary sclerosing cholangitis have been investigated.

94 e gene polymorphisms associated with primary sclerosing cholangitis have been investigated.

95 Liver histology of sclerosing cholangitis improved, and extent of fibrosis

96 Primary sclerosing cholangitis in children can mimic autoimmune

97 ctive and accurate way of diagnosing primary sclerosing cholangitis in comparison with endoscopic ret

98 id transporter (ASBT), blocks progression of sclerosing cholangitis in mdr2(-/-) mice.

99 higher rate of retransplantation for primary sclerosing cholangitis in most centers.

100 hepatitis in children may be associated with sclerosing cholangitis in the absence of inflammatory bo

101 1,4-dihydrocollidine (DDC) feeding to induce sclerosing cholangitis in wild-type (WT) and knockout (M

102 ure research efforts should focus on primary sclerosing cholangitis, in addition to primary biliary c

103 sights have arisen from studies of secondary sclerosing cholangitis, in which a similar clinical prof

104 Symptoms of primary sclerosing cholangitis include fatigue, jaundice, prurit

105 sociated with ulcerative colitis and primary sclerosing cholangitis, inflammatory diseases with a hig

106 Primary sclerosing cholangitis-inflammatory bowel disease probab

107 s such as primary biliary cirrhosis, primary sclerosing cholangitis, intrahepatic cholestasis of preg

108 cholangitis (IAC), also called IgG4-related sclerosing cholangitis (IRSC), to the spectrum of chroni

109 Primary sclerosing cholangitis is a chronic cholestatic disease

110 Primary sclerosing cholangitis is a chronic cholestatic liver di

111 Primary sclerosing cholangitis is a chronic cholestatic liver di

112 Primary sclerosing cholangitis is a chronic cholestatic liver di

113 Primary sclerosing cholangitis is a chronic cholestatic liver di

114 Primary sclerosing cholangitis is a chronic immune-mediated live

115 Primary sclerosing cholangitis is a chronic, progressive cholang

116 The genetic susceptibility to primary sclerosing cholangitis is associated, in part, with the

117 Liver histology in primary sclerosing cholangitis is characterized by a portal infl

118 Treatment of primary sclerosing cholangitis is confined to supportive measure

119 ate that the colitis associated with primary sclerosing cholangitis is pathophysiologically distinct

120 Primary sclerosing cholangitis is strongly linked to inflammator

121 ic heterogeneity among patients with primary sclerosing cholangitis is supported, and further gene po

122 Primary sclerosing cholangitis is the classic hepatobiliary mani

123 The etiopathogenesis of primary sclerosing cholangitis is unknown.

124 The best-studied drug in primary sclerosing cholangitis is ursodeoxycholic acid, which, d

125 vealed pancreatic duct strictures in two and sclerosing cholangitis-like appearance in one.

126 r activation in vitro and in vivo in primary sclerosing cholangitis liver specimens.

127 malignant PVT, after exclusion of those with sclerosing cholangitis, liver transplants, choledocholit

128 PBC livers, compared with normal and primary sclerosing cholangitis livers.

129 cy included concomitant diagnosis of primary sclerosing cholangitis, longstanding colitis (>10 years)

130 4 patients included autoimmune pancreatitis, sclerosing cholangitis, lymphoplasmacytic aortitis, sali

131 It is suggested that primary sclerosing cholangitis may have a bacterial cause.

132 Primary sclerosing cholangitis may overlap with autoimmune hepat

133 Sclerosing cholangitis may recur after transplantation,

134 Primary sclerosing cholangitis mice and patients have increased

135 Abcb4(-/-); Mdr2(-/-)) knockout (KO) mice, a sclerosing cholangitis model.

136 model to explain the development of primary sclerosing cholangitis must take into account the fact t

137 era from patients with PBC (n = 47), primary sclerosing cholangitis (n = 15), and healthy volunteers

138 ancreatitis (n = 34) from those with primary sclerosing cholangitis (n = 17) and CA (n = 17).

139 ra from patients with PBC (n = 105), primary sclerosing cholangitis (n = 70), and rheumatoid arthriti

140 Strictures in patients with primary sclerosing cholangitis (n = 86) were analyzed separately

141 he causes of death were related to secondary sclerosing cholangitis (n=1), cardiac failure (n=1), and

142 disease: primary biliary cirrhosis (n= 19), sclerosing cholangitis (n=6), and autoimmune hepatitis (

143 imary biliary cirrhosis (PBC, n=76), primary sclerosing cholangitis (n=81), hepatitis C virus (HCV) (

144 ing pancreatitis and cholangitis, n = 21; b) Sclerosing cholangitis, n = 9; c) Sclerosing pancreatiti

145 ectable or arising in the setting of primary sclerosing cholangitis, neoadjuvant chemoradiotherapy fo

146 in nonalcoholic fatty liver disease, primary sclerosing cholangitis, neonatal hemochromatosis, acute

147 Neonatal ichthyosis and sclerosing cholangitis (NISCH) syndrome is a liver disea

148 vancements in the areas of childhood primary sclerosing cholangitis, nonalcoholic fatty liver disease

149 4-dihydrocollidine (DDC) feeding (a model of sclerosing cholangitis) or bile duct ligation (BDL).

150 st LT for primary biliary cirrhosis, primary sclerosing cholangitis, or alcoholic cirrhosis (group I)

151 all P = .003), as well as absence of primary sclerosing cholangitis (P = .011).

152 tis C virus (P = 0.01, HR = 1.6) and primary sclerosing cholangitis (P = 0.03, HR = 2.9).

153 ns for celiac disease (P = 0.22) and primary sclerosing cholangitis (P = 0.078) were not associated w

154 human liver samples from control or primary sclerosing cholangitis patients were evaluated for MC ma

155 s been demonstrated in a subgroup of primary sclerosing cholangitis patients, which may indicate an o

156 ve CCA detection, particularly among primary sclerosing cholangitis patients.

157 bile ducts from the hilar region of primary sclerosing cholangitis patients.

158 Underlying primary sclerosing cholangitis, percutaneous biliary intubation,

159 e most studied medical treatment for primary sclerosing cholangitis; pilot studies suggest a possible

160 for low-grade dysplasia, strictures, primary sclerosing cholangitis, post-inflammatory polyps, family

161 hepatitis (HR, 1.35; P < 0.001), and primary sclerosing cholangitis pre-LT (compared with hepatitis C

162 In liver tissues from patients with primary sclerosing cholangitis, primary biliary cholangitis, chr

163 er tissue samples from patients with primary sclerosing cholangitis, primary biliary cholangitis, hep

164 NA (mRNA) in PBC liver compared with primary sclerosing cholangitis (PSC) (P <.05) or normal controls

165 The prevalence of primary sclerosing cholangitis (PSC) among patients with inflamm

166 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) and assessed both vertebral

167 sis occurs during the progression of primary sclerosing cholangitis (PSC) and is characterized by acc

168 Primary sclerosing cholangitis (PSC) and primary biliary cholang

169 ding bile duct epithelium) varies in primary sclerosing cholangitis (PSC) and primary biliary cirrhos

170 Patients with primary sclerosing cholangitis (PSC) are at an increased risk fo

171 Patients with primary sclerosing cholangitis (PSC) are at increased risk for d

172 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent autoimmune c

173 tologic scoring systems specific for primary sclerosing cholangitis (PSC) are not validated.

174 primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) are scarce.

175 Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are uncommon liver diseases

176 s serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve surviv

177 nd hepatic histology compatible with primary sclerosing cholangitis (PSC) but normal findings on chol

178 eased donor livers for patients with primary sclerosing cholangitis (PSC) due to the weighting of the

179 proximately 60%-80% of patients with primary sclerosing cholangitis (PSC) have concurrent ulcerative

180 giography (MRC) for the diagnosis of primary sclerosing cholangitis (PSC) have described comparable a

181 developing varices in patients with primary sclerosing cholangitis (PSC) have not been well studied

182 ulation-level data on the effects of primary sclerosing cholangitis (PSC) in patients with inflammato

183 The epidemiology of primary sclerosing cholangitis (PSC) in the United States is unk

184 Primary sclerosing cholangitis (PSC) is a cholestatic liver dise

185 Primary sclerosing cholangitis (PSC) is a chronic bile duct dise

186 Primary sclerosing cholangitis (PSC) is a chronic cholestatic di

187 Primary sclerosing cholangitis (PSC) is a chronic cholestatic li

188 Primary sclerosing cholangitis (PSC) is a chronic cholestatic li

189 Primary sclerosing cholangitis (PSC) is a chronic cholestatic li

190 Primary sclerosing cholangitis (PSC) is a chronic fibroinflammat

191 Primary sclerosing cholangitis (PSC) is a chronic inflammatory c

192 Primary sclerosing cholangitis (PSC) is a chronic inflammatory l

193 Primary sclerosing cholangitis (PSC) is a chronic, fibroinflamma

194 Primary sclerosing cholangitis (PSC) is a chronic, idiopathic, f

195 Primary sclerosing cholangitis (PSC) is a disease of unknown cau

196 Primary sclerosing cholangitis (PSC) is a heterogeneous and prog

197 Primary sclerosing cholangitis (PSC) is a rare but important liv

198 Primary sclerosing cholangitis (PSC) is a rare progressive disor

199 Primary sclerosing cholangitis (PSC) is a rare, but serious, cho

200 Because primary sclerosing cholangitis (PSC) is a risk factor for CCA, s

201 Primary sclerosing cholangitis (PSC) is a severe liver disease o

202 Primary sclerosing cholangitis (PSC) is an idiopathic, progressi

203 Primary sclerosing cholangitis (PSC) is an incurable cholangiopa

204 BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary

205 Primary sclerosing cholangitis (PSC) is increasingly diagnosed i

206 Patients with primary sclerosing cholangitis (PSC) may be at higher risk of ma

207 time may predict colectomy, whereas primary sclerosing cholangitis (PSC) may be protective.

208 Patients with primary sclerosing cholangitis (PSC) may develop and bleed from

209 isk of biliary tract cancer (BTC) in primary sclerosing cholangitis (PSC) may exceed 20%, and BTC is

210 Pathogenesis of primary sclerosing cholangitis (PSC) may involve impaired bile a

211 features of patients with small-duct primary sclerosing cholangitis (PSC) occurring with and without

212 stricture formation in patients with primary sclerosing cholangitis (PSC) or after liver transplantat

213 ed specifically in cholangiocytes of primary sclerosing cholangitis (PSC) patients and in mice subjec

214 Primary sclerosing cholangitis (PSC) patients pose a particularl

215 Primary sclerosing cholangitis (PSC) patients suffer from comorb

216 Primary sclerosing cholangitis (PSC) predisposes individuals to

217 o summarize publications on juvenile primary sclerosing cholangitis (PSC) published over the past 5 y

218 The pathogenesis of primary sclerosing cholangitis (PSC) remains poorly understood.

219 Primary sclerosing cholangitis (PSC) represents a major unmet me

220 T cells from patients with primary sclerosing cholangitis (PSC) show a prominent IL-17 resp

221 T cells from patients with primary sclerosing cholangitis (PSC) show a prominent interleuki

222 For patients with primary sclerosing cholangitis (PSC) suffering from bacterial ch

223 Primary sclerosing cholangitis (PSC) was present in 31/126 CCA p

224 underwent liver transplantation for primary sclerosing cholangitis (PSC) were analyzed using person-

225 mens, including 64 with PBC, 19 with primary sclerosing cholangitis (PSC), 6 with non-A, non-B hepati

226 Primary sclerosing cholangitis (PSC), a chronic inflammatory liv

227 The pathogenesis of primary sclerosing cholangitis (PSC), a progressive biliary trac

228 Primary sclerosing cholangitis (PSC), age, history of cholecyste

229 ects, including 28 with PBC, 13 with primary sclerosing cholangitis (PSC), and 18 healthy controls.

230 ses primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and alcoholic liver diseas

231 plantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and validat

232 rimary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are frequently associated

233 Several conditions, such as primary sclerosing cholangitis (PSC), are risk factors.

234 atic tissue from patients with AP or primary sclerosing cholangitis (PSC), as well as from mice.

235 ogy and natural history of pediatric primary sclerosing cholangitis (PSC), autoimmune sclerosing chol

236 In primary sclerosing cholangitis (PSC), bile fluid is frequently c

237 tolithiasis and 20 archival cases of primary sclerosing cholangitis (PSC), both of which are risk con

238 bowel disease may be accompanied by primary sclerosing cholangitis (PSC), but seldom primary biliary

239 arly primary biliary cholangitis and primary sclerosing cholangitis (PSC), evolve over time with anat

240 Primary sclerosing cholangitis (PSC), first described in the mid

241 e been demonstrated in patients with primary sclerosing cholangitis (PSC), must be accompanied by fun

242 for detecting cholangiocarcinoma in primary sclerosing cholangitis (PSC), particularly when used seq

243 The influence of sex on primary sclerosing cholangitis (PSC), pre and post-liver transpl

244 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment

245 In primary sclerosing cholangitis (PSC), the focus of this review,

246 fibrosis in animal models and human primary sclerosing cholangitis (PSC).

247 ng disease activity and prognosis in primary sclerosing cholangitis (PSC).

248 iated biliary injury is a feature of primary sclerosing cholangitis (PSC).

249 e, other benign disease, tumour, and primary sclerosing cholangitis (PSC).

250 which is increased in patients with primary sclerosing cholangitis (PSC).

251 or management of adult patients with primary sclerosing cholangitis (PSC).

252 andard of reference for diagnosis of primary sclerosing cholangitis (PSC).

253 and disease course in patients with primary sclerosing cholangitis (PSC).

254 not been well studied in those with primary sclerosing cholangitis (PSC).

255 deoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC).

256 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).

257 primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).

258 nd predict outcomes in patients with primary sclerosing cholangitis (PSC).

259 nts with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC).

260 primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).

261 o be ineffective in the treatment of primary sclerosing cholangitis (PSC).

262 e obtained from patients affected by primary sclerosing cholangitis (PSC).

263 rimary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).

264 the serum and liver of patients with primary sclerosing cholangitis (PSC).

265 iocyte senescence has been linked to primary sclerosing cholangitis (PSC).

266 n of cholangiopathies, in particular primary sclerosing cholangitis (PSC).

267 s; however, no information exists in primary sclerosing cholangitis (PSC).

268 ated inflammatory diseases including primary sclerosing cholangitis (PSC).

269 reported in 9%-15% of patients with primary sclerosing cholangitis (PSC); it is not clear whether th

270 static diseases such as primary or secondary sclerosing cholangitis (PSC, SSC) and primary biliary ch

271 ignancy was highest in patients with primary sclerosing cholangitis (PSC; 22% at 10 years) or alcohol

272 ary biliary cirrhosis (PBC; n=3052), primary sclerosing cholangitis (PSC; n=3854), hepatitis C virus

273 reater primary dysfunction GF, while primary sclerosing cholangitis (PSC; P=0.0002) implied greater v

274 imary biliary cholangitis [PBC], and primary sclerosing cholangitis [PSC]), we built a comprehensive

275 bacteria in the etiopathogenesis of primary sclerosing cholangitis remains to be determined.

276 carcinoma (HCC) (SMR 38.4-18.8), and primary sclerosing cholangitis (SMR 11.0-4.2), and deterioration

277 le modeling using RC, FISH, age, and primary sclerosing cholangitis status can be used to estimate th

278 , trisomy FISH, suspicious cytology, primary sclerosing cholangitis status, and age were associated w

279 Yet different from patients with primary sclerosing cholangitis, the expression of CCL25 remained

280 do not confer any susceptibility to primary sclerosing cholangitis; the role of intercellular adhesi

281 ease, non-alcoholic steatohepatitis, primary sclerosing cholangitis, total parenteral nutrition-assoc

282 emonstrated in biliary lithiasis and primary sclerosing cholangitis, two cholangiopathies regarded as

283 tween inflammatory bowel disease and primary sclerosing cholangitis underscores the need to further u

284 Cirrhosis not related to primary sclerosing cholangitis was associated with both intrahep

285 Primary sclerosing cholangitis was more strongly associated with

286 d inflammatory bowel disease without primary sclerosing cholangitis was not associated with any CCA s

287 A paucity of research studies on primary sclerosing cholangitis was noted in this review and futu

288 with inflammatory bowel disease and primary sclerosing cholangitis was the identification of an incr

289 Sclerosing cholangitis was the most important risk facto

290 For all recipients, female sex and primary sclerosing cholangitis were associated with improved sur

291 disease, and those with concomitant primary sclerosing cholangitis were at increased risk.

292 Patients suspected to have secondary sclerosing cholangitis were excluded.

293 ther inflammatory disorders (such as primary sclerosing cholangitis), whereas it decreases when patie

294 ic cholangitides, the most common is primary sclerosing cholangitis, which is associated with inflamm

295 second patient was a 26-year-old female with sclerosing cholangitis who presented with encephalopathy

296 icult, particularly in patients with primary sclerosing cholangitis, who are at risk of developing th

297 ciated primary biliary cirrhosis and primary sclerosing cholangitis with genes encoding major histoco

298 itis with pancreatic pseudotumour, n = 7; e) Sclerosing cholangitis with hepatic pseudotumour, n = 3;

299 mples from patients with and without primary sclerosing cholangitis with higher levels of sensitivity

300 Sclerosing cholangitis with strong autoimmune features i